Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

MPN Congress 2022 | The role of rusfertide in polycythemia vera

Richard Silver • 18 Oct 2022

MPN Congress 2022

Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Hydroxyurea Interferon Rusfertide

Richard Silver, MD, Weill Cornell Medical College, New York, NY, highlights the mechanism of action of rusfertide in polycythemia vera (PV), outlining the advantages of this drug. Prof. Silver explains that rusfertide treatment reduces and could even eliminate the need for phlebotomy in these patients. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Interferon in polycythemia vera: long - term experience from a single center

Richard Silver • 10 Nov 2022

The role of interferon in polycythemia vera & perspectives on the management of low-risk patients

Richard Silver • 18 Oct 2022

Management of patients with PV who are intolerant to interferon and who develop post-polycythemic MF

Richard Silver • 18 Oct 2022

Looking forward to the 2022 MPN Congress

Richard Silver • 18 Oct 2022

Related Videos

Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH

Carlo Dufour • 15 Apr 2024

Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting

Alex Rampotas • 16 Apr 2024

Personalized risk assessment for transplantation in primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024

Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024